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Available online 27 May 2016Background: Cholesterol embolization syndrome is a rare and under-diagnosed clinical entity. Vascular
procedures such as angiography of vascular surgery have been identiﬁed as triggering factor.
Case report: A 71-year-old man presented with acute ST segment elevated anterior myocardial infarction and
coronary stenting was performed. At the clinic follow-up, coloured skin lesions were observed at both hands
and feet. During follow-up, progressive deterioration in renal functions also developed gradually. Supportive
therapy was provided in addition to standard treatment for myocardial infarction.
Conclusion: In conclusion cholesterol embolization syndrome should be considered in any patient presenting
with cutaneous features and renal failure after invasive vascular procedure.
©2016 The Society of Cardiovascular Academy. Production and hosting by Elsevier B.V. All rights reserved. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Cholesterol embolization syndrome (CES) is caused by distal embo-
lisation of cholesterol crystals from aortic atheromatous plaques, which
then result in end-organ damage.1 Herein, a case of probable CES with
cutaneous manifestation on all extremities and renal failure after
performing primary percutaneous coronary intervention in patient
with acute anterior myocardial infarction was presented.Case report
A 71-year-oldman presented with chest pain radiating to both arms
accompanied by nausea and sweating came to emergency department.
He had a history of hypertension and diabetes mellitus. He was a non-
smoker and had no other remarkable history of medical condition. At
the admission, his blood pressure was 100/60 mmHg and heart rate
was 88 beats/min. Electrocardiogramwas in sinus rhythm and revealed
ST segment elevation over leads V1–V6 in accordance with acute ST
segment elevated anterior myocardial infarction. Echocardiography
showed hypokinesia of the anterior wall, anterior septum and left ven-
tricular apex with left ventricular ejection fraction of 48%. Left ventricle
end-diastolic diameter and left atrial diameter were 52mmand 36mm,diovascular Academy.
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y. Production and hosting by Elsevrespectively. However, left ventricular thrombi were not detected. In
laboratory ﬁndings glucose level was 188 mg/dl, HbA1c was 7.2 and
total cholesterol level was184 mg/dl. Aspirin and clopidogrel were
given and heparin was used for anticoagulation. He transferred to coro-
nary angiography laboratory. Emergent coronary angiography revealed
totally occluded left anterior descending (LAD) coronary artery. Circum-
ﬂex and right coronary artery angiography showed non-signiﬁcant ste-
nosis. LAD lesion was crossed with guidewire and drug-eluting stent
was implanted. Thrombolysis in myocardial infarction III (TIMI III)
ﬂow was observed. After the procedure the patient was transferred to
coronary care unit and two days later transferred to cardiology clinic.
At the clinic follow-up, painful, blue-coloured, macule lesions were ob-
served at both hands and feet (Figs. 1, 2). These lesions became larger
over the ensuing days. His blood pressure was 115/70 mmHg with a
pulse of 75 beats per minute, his respiration was 16 per minute and
the body temperature was 36.8 °C. His oxygen saturation was 96% on
air and all peripheral pulses were present. During follow-up, progres-
sive deterioration in renal functions developed gradually and his initial
serum creatinine level aroused from 1.12 mg/dL to 3.02 mg/dL over the
next days. Laboratory investigation showed hypereosinophilia (10%),
increased erythrocyte sedimentation rate (68 mm/h) and normal
platelet count. Serum levels of antinuclear antibody and antineutrophil
cytoplasmic antibody tests were in normal range. Close chronological
association with coronary intervention, the signs and the laboratory
results suggested the diagnosis of probable CES. Anti-inﬂammatory
therapy or corticosteroid therapy was not started due to the acute
myocardial infarction. Antiplatelet therapy was maintained. High dose
statin therapy with rosuvastatin 40 mg/day was continued. Supportive
therapy was provided by effective hydration and wound care. Atier B.V. All rights reserved. This is an open access article under the CC BY-NC-ND license
Fig. 1. Clinical image of purple coloured skin manifestation on both of the hands.
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creatinine level of the patient decreased to 1.9 mg/dL three weeks
after. Six month after the admission, the patient remains asymptomatic
with a creatinine level of 1.33mg/dL and a serumurea level of 64mg/dL.
To date, there has been no adverse event with the patient.
Discussion
We hereby described a case of CES with renal and cutaneous in-
volvement affecting extremities after performing coronary intervention
in patientwith acutemyocardial infarction. This casewas unique in that
cutaneous lesions were observed both on lower extremities and also
upper extremities.
CES is a systemic disorder that can spread to multiple organs
resulting renal failure, heart failure, gastrointestinal ischemia and skin
necrosis. Most affected organs related to CES are the brain, the kidney,
the gastrointestinal tract and the skin. Central nervous system involve-
ment may lead to confusion or memory loss.1 In our patient, there was
no symptom or sign of brain injury. The retinal artery occlusion may
present with Hollenhorst plaques on retina examination. Embolization
to the kidneys has usually patchy distribution. Elevation of serumFig. 2. Clinical image of painful macules on the feet.creatinine and proteinuria are the main laboratory ﬁndings.2 In the
present case, serum creatinine level increased progressively but with
supportive care not reached to end-stage renal disease. Cutaneousman-
ifestations of CES include livedo reticularis, gangrene, cyanosis, nodules,
macule, ulceration and purpura. Purple or blue discoloration of the foot
lead to call ‘ blue toe syndrome ‘ synonymouswith CES. Cutaneousman-
ifestations almost always located to the lower extremities and rarely ex-
tended to upper extremities.3 In our case bluish lesions were observed
not only on the feet but also on the hands. Risk factors for CES are
male gender, smoking, advanced age, hypertension and aortic aneu-
rysm. Development of clinical event is triggered by invasive procedures
of aorta, anticoagulation and thrombolysis.4 Mainly, a plaque located at
proximal, large-calibre artery is ruptured by iatrogenic trauma such as
catheter manipulation or spontaneously. Embolization of plaque debris
to small ormedium sized arteries leads tomechanical occlusion and for-
eign body inﬂammatory response which result in end-organ damage.
Common source of atheroembolism is the abdominal aorta thus embo-
lism to upper extremities is unusual. CES during coronary angioplasty is
uncommon with the incidence of 0.6%.5
In the diagnosis of CES, constitutional symptoms and signs are
frequent in addition to speciﬁc end-organ damage presentation. Leuko-
cytosis with hypereosinophilia, arise in erythrocyte sedimentation rate
and C-reactive protein and a decrease in serum complement level may
be seen in laboratory tests. Biopsy for any target organ such as kidney
or skin could also be obtained for histopathological conﬁrmation. How-
ever, none of the test is speciﬁc for CES so clinical suspicion is very cru-
cial in the diagnosis of CES. Skin biopsy was not performed in this case.
Although pathological ﬁndings may be seen in cases, cholesterol cleft
identiﬁcation is limited. Furthermore, in delayed biopsies necrotizing
vasculitismay also be seen.6 In differential diagnosis, sepsis, disseminat-
ed intravascular coagulation (DIC) and heparin-induced thrombocyto-
penia (HIT) should also keep in mind. While the prolonged activated
partial thromboplastin time and prothrombin time and also low levels
of protein-C and antithrombin are associated with DIC, coagulation
tests is usually normal in HIT with increase in platelet count after cessa-
tion of heparin. Positive blood culture and positive sepsis criteria are
main determinants in sepsis without DIC. As CES is a clinical entity, in
this case diagnosis of CES is conﬁrmed by using symptoms, signs,
laboratory ﬁndings and close chronological association with coronary
intervention.
There is no widely acceptable treatment for CES. Supportive
therapy is aimed at end-organ damage. Risk factor modiﬁcation for
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tension, diabetes mellitus and hyperlipidemia. Corticosteroid use
may control the inﬂammation. Statins are considered as key therapy
for stabilising atherosclerotic plaque. Antiplatelet agents, renin-
angiotensin system blockers should be considered for therapy. Surgical
repair of the diseased aorta should also be used for therapy.7 In our pa-
tient, antiplatelet therapy maintained due to acute myocardial infarc-
tion and coronary stenting. Oral rosuvastatin was administered at a
dose of 40 mg/day. The skin lesions improved gradually in two month
follow-up. Serum creatinine level was also decreased to 1.9 mg/dL.
High clinical suspicion is critical for the diagnosis of this clinical en-
tity. CES should be considered when the patient has acute renal failure
and speciﬁc skin lesions in the extremities after an invasive vascular
procedure.References
1. Kronzon I, Saric M. Cholesterol embolization syndrome. Circulation 2010;122:
631–641.
2. Scolari F, Tardanico R, Zani R, et al. Cholesterol crystal embolism: a recognizable cause
of renal disease. Am J Kidney Dis 2000;36:1089–1109.
3. Falanga V, Fine MJ, Kapoor WN. The cutaneous manifestations of cholesterol crystal
embolization. Arch Dermatol 1986;122:1194–1199.
4. Funabiki K, Masuoka H, Shimizu H, et al. Cholesterol crystal embolization (CCE) after
cardiac catheterization: a case report and a review of 36 cases in the Japanese litera-
ture. Jpn Heart J 2003;44:767–774.
5. Johnson LW, Esente P, Giambartolomei A, et al. Peripheral vascular complications of
coronary angioplasty by the femoral and brachial techniques. Catheter Cardiovasc
Diagn 1994;31:165–172.
6. Grau R. Pseudovasculitis: mechanisms of vascular injury and clinical spectrum. Curr
Rheumatol Rep 2002;4:83–89.
7. Belenfant X, Meyrier A, Jacquot C. Supportive treatment improves survival in
multivisceral cholesterol crystal embolism. Am J Kidney Dis 1999;33:840–850.
